The Scientist Using AI to Engineer the Next Generation of Drugs: Geoffrey von Maltzahn

Venture into the realm of biotech entrepreneurship with Geoffrey von Maltzahn, the mastermind behind a multitude of ground-breaking companies that fuse biology and data science to revolutionize human health and sustainability. Named among Bloomberg's 50 Ones to Watch, Business Insider's 30 Biotech Leaders under 40 and noted as one of Codex's World's Top 50 Innovators, Geoffrey stands as a prominent figure in the realm of biotech entrepreneurship. He has co-founded companies which have massed over $10 billion in market capitalization, including: Flagship Pioneering, Generate Biomedicines, Quotient Therapeutics, Tessera Therapeutics’, the list goes on. As the current CEO of six of these ventures, he is shaping industries with cutting edge technologies like Gene Writing™️ and carbon farming.We explore: - Harnessing the power of AI.- The intersection of biology and technology.- Entrepreneurial success.- The future of human health.- Gene editing and personalised medicine. - Achieving your peak performance. Chapters:00:00 – Welcome to High Net Purpose00:18 – Meet Geoffrey von Maltzahn: Biotech Visionary & Builder00:37 – The Dawn of a New Era in Medical Discovery01:23 – His Purpose: Reimagining Human Health Through Science02:52 – What Biological Engineering Will Mean for the World03:09 – From MIT to Flagship: Geoffrey’s Foundational Journey14:44 – Creating Generate Biomedicines: AI Meets Drug Discovery25:41 – Gene Writing: How Tessera Is Rewriting the Rules33:44 – Building Breakthrough Teams & Navigating Setbacks44:49 – What’s Next: Future Vision and Big Bets51:32 – Final Reflections & Closing Thoughts Hosted on Acast. See acast.com/privacy for more information.